SummaryPast reports have suggested that antiphospholipid (aPL) antibodies may emerge as a response to antipsychotics treatment, as a high prevalence of aPL antibodies in antipsychotics users has been observed. However, no control group of non-medicated psychiatric patients was included in these reports. In a cross sectional study we determined the prevalence of aPL antibodies in 333 psychiatric inpatients. We compared the proportions of positive aPL antibodytests between users and non-users of antipsychotics with adjustments for potential confounders. The proportion of antipsychotics users carrying at least one aPL antibody ranged from 10Á8% to 27Á0% compared with 6Á8% to 27Á2% in non-users (P = 0Á24, P = 0Á24) depending on the method of detection of lupus anticoagulant (LA). The prevalence of LA detected by dilute Russell viper venom time or partial thromboplastin time-LA was not different between antipsychotics users and non-users (8Á1% vs. 5Á4%, P = 0Á53 and 18Á4% vs. 18Á2%, P = 0Á22), as well as the prevalence of IgM and IgG anti-b2-glycoprotein-I antibodies, IgM and IgG anti-cardiolipin antibodies(3Á8% vs. 2Á0%, P = 0Á75, 0Á0% vs. 0Á0%, P = not applicable, 1Á1 vs. 1Á4%, P = 0Á91, 2Á7% vs. 3Á4%, P = 0Á71). In conclusion, aPL antibodies were frequently found in patients with psychiatric diseases and no significant increase in the prevalence of aPL antibodies was observed in antipsychotics users.